Factors predictive of the development of levodopa-induced dyskinesia and Wearing-Off in Parkinson's disease.
作者信息
Rajput Ali H
机构信息
University of Saskatchewan/Saskatoon Health Region, Saskatoon, Saskatchewan, Canada.
出版信息
Mov Disord. 2014 Mar;29(3):429. doi: 10.1002/mds.25800. Epub 2013 Dec 27.
Abstract
摘要
相似文献
1
Factors predictive of the development of levodopa-induced dyskinesia and Wearing-Off in Parkinson's disease.
Mov Disord. 2014 Mar;29(3):429. doi: 10.1002/mds.25800. Epub 2013 Dec 27.
2
Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
Mov Disord. 2013 Jul;28(8):1064-71. doi: 10.1002/mds.25364. Epub 2013 Apr 29.
3
Initiating levodopa therapy for Parkinson's disease.
Mov Disord. 2014 Mar;29(3):430. doi: 10.1002/mds.25805. Epub 2014 Jan 9.
4
Rating scales for dyskinesias in Parkinson's disease.
Mov Disord. 1999;14 Suppl 1:48-53.
5
Should there be less emphasis on levodopa-induced dyskinesia in Parkinson's disease?
Mov Disord. 2019 Jun;34(6):816-819. doi: 10.1002/mds.27691. Epub 2019 Apr 14.
6
The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease.
Mov Disord. 1999;14 Suppl 1:13-8.
7
Extended-release amantadine (Gocovri) for dyskinesia in Parkinson's disease.
Med Lett Drugs Ther. 2017 Dec 4;59(1535):198-200.
8
Levodopa-induced dyskinesia in an autopsy-proven case of progressive supranuclear palsy.
Mov Disord. 2002 Sep;17(5):1089-90. doi: 10.1002/mds.10246.
9
A Web Resource for Levodopa-Induced Dyskinesia Genetics in Parkinson's Disease.
Neuroinformatics. 2017 Jul;15(3):297-300. doi: 10.1007/s12021-017-9327-z.
10
L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach.
Mov Disord. 1999;14 Suppl 1:19-32.
引用本文的文献
1
Identifying Risk Factors and Constructing Predictive Models for Wearing-Off and Dyskinesia in Chinese Patients With Parkinson's Disease on Long-Term Levodopa Therapy.
CNS Neurosci Ther. 2025 Aug;31(8):e70544. doi: 10.1111/cns.70544.
2
FTO-targeted siRNA delivery by MSC-derived exosomes synergistically alleviates dopaminergic neuronal death in Parkinson's disease via m6A-dependent regulation of ATM mRNA.
J Transl Med. 2023 Sep 22;21(1):652. doi: 10.1186/s12967-023-04461-4.
3
Seed Aqueous Extract Improved Neuroprotective and Acetylcholinesterase Inhibitory Effects Compared with Synthetic L-Dopa.
Molecules. 2022 May 13;27(10):3131. doi: 10.3390/molecules27103131.
4
Balancing mTOR Signaling and Autophagy in the Treatment of Parkinson's Disease.
Int J Mol Sci. 2019 Feb 8;20(3):728. doi: 10.3390/ijms20030728.
5
Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist.
Curr Neuropharmacol. 2016;14(4):356-63. doi: 10.2174/1570159x14666151208114634.
6
Saskatchewan movement disorders program.
Can J Neurol Sci. 2015 Mar;42(2):74-87. doi: 10.1017/cjn.2015.13.
本文引用的文献
1
Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
Mov Disord. 2013 Jul;28(8):1064-71. doi: 10.1002/mds.25364. Epub 2013 Apr 29.
2
Course in Parkinson disease subtypes: A 39-year clinicopathologic study.
Neurology. 2009 Jul 21;73(3):206-12. doi: 10.1212/WNL.0b013e3181ae7af1.
3
The effect of l-3,4-dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism. 1961.
Wien Klin Wochenschr. 2001 Nov 15;113(22):851-4.
4
Chronic low-dose levodopa therapy in Parkinson's disease: an argument for delaying levodopa therapy.
Neurology. 1984 Aug;34(8):991-6. doi: 10.1212/wnl.34.8.991.
5
Aromatic amino acids and modification of parkinsonism.
N Engl J Med. 1967 Feb 16;276(7):374-9. doi: 10.1056/NEJM196702162760703.
Zotero 插件